Form 4: Director Elizabeth Mooney Receives BeOne Medicines Equity

Director Elizabeth Mooney acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Summary

• Director Elizabeth Mooney was granted 18,980 restricted share units (RSUs) in BeOne Medicines Ltd. (ONC).
• The transaction occurred on June 11, 2026.
• The shares were acquired at a price of $0, representing equity-based compensation.
• The RSUs are subject to a vesting schedule tied to the earlier of the first anniversary of the grant or the next annual general meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is contingent upon continued service on the board of directors.
• Vesting may be subject to specific acceleration triggers defined in the company's Independent Non-Executive Director Compensation Policy.

Future Outlook

The RSUs are expected to vest on the earlier of the first anniversary of the grant date (June 11, 2027) or the date of the next annual general meeting.

Management Comments

• The grant is subject to the company's Independent Non-Executive Director Compensation Policy.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard corporate governance practice to ensure board members have a vested interest in long-term company performance.

Comparison to Industry Standards

• The use of restricted share units for director compensation is consistent with standard practices for publicly traded biotechnology companies.
• Vesting schedules tied to annual general meetings are common in the industry to align director tenure with the annual election cycle.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 18,980 restricted share units on the earlier of June 11, 2027, or the next annual general meeting.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Transaction, Director Compensation, Restricted Share Units